Dr. Reddy’s announces the launch of Ibandronate Sodium tablets
02 Jul 2012
Hyderabad-based Dr Reddy's Laboratories today said that it has launched Ibandronate Sodium tablets (150 mg), a bioequivalent generic version of Boniva tablets in the US market on June 29, 2012 following the approval by the USFDA of Dr. Reddy's ANDA for Ibandronate sodium tablets.
The Boniva brand and generic had US sales of approximately $486 million for the last 12 months ending March 2012 according to IMS Health.
Dr. Reddy's Ibandronate sodium tablets in 150 mg are available in cartons of 3 blister packs containing 1 tablet each (once monthly dosing).
Boniva is a prescription medication used to treat or prevent osteoporosis in women after menopause, and is manufactured by GlaxoSmithKline and Roche Holding AG. The drug has been linked to side effects, for which it faced lawsuits in 2009.
In 2007, Roche had filed lawsuits against Dr Reddy's, which had filed for FDA approval for its version of Boniva, but Roche claimed the drug was covered by one patent or another through 2023.
